Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-DC008561 | Panoply™ Human LATS2 Knockdown Stable Cell Line | Inquiry |
| CSC-SC008561 | Panoply™ Human LATS2 Over-expressing Stable Cell Line | Inquiry |
| CSC-RT0703 | Human LATS2 Knockout Cell Line-HeLa | Inquiry |
| CLKO-0208 | LATS2 KO Cell Lysate-HeLa | Inquiry |
| CSC-RT2616 | Mouse Lats2 Knokcout Cell Line-4T1 | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| AD09034Z | Human Lats2 adenoviral particles | Inquiry |
| LV16792L | human LATS2 (NM_014572) lentivirus particles | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| SHH328691 | shRNA set against Human Lats2 (NM_014572.2) | Inquiry |
| SHH328699 | shRNA set against Rat Lats2 (NM_001107267.1) | Inquiry |
| SHW012572 | shRNA set against Danio rerio LATS2 (NM_001123307) | Inquiry |
| SHW012707 | shRNA set against Danio rerio LATS2 (NM_001128256) | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| CDCB174047 | Danio rerio LATS2 ORF Clone (NM_001123307) | Inquiry |
| CDFR006988 | Rat Lats2 cDNA Clone(NM_001107267.1) | Inquiry |
| MiUTR1H-05588 | LATS2 miRNA 3'UTR clone | Inquiry |
| SKO0106 | LATS2 Validated sgRNA vector | Inquiry |
| CDCB174182 | Danio rerio LATS2 ORF Clone (NM_001128256) | Inquiry |
| CDCB183793 | Rabbit LATS2 ORF clone (XM_008259923.1) | Inquiry |
| CDCL126329 | Human LATS2 ORF clone (NM_014572.2) | Inquiry |
| CDCR373988 | Rat Lats2 ORF Clone(NM_001107267.1) | Inquiry |
Recent Progress
LATS2 is a key component of the Hippo signaling pathway. It was reported that LATS2 inhibits Wnt/β-catenin-mediated oncogenesis by disrupting the β-catenin/BCL9 interaction. Nocodazole, an antimicrotubule drug, potently induced LATS2 to suppress tumor growth in vivo by targeting β-catenin/BCL9. The results suggest that LATS2 is not only a key tumor suppressor in human cancer, but may also be an important target for anticancer therapy.
Fig. 1. Domain architecture of the LATS2. (Li et al, 2013)
Another research displayed that mammalian LATS orthologues exhibit distinct expression profiles according to germ cell layer origin. LATS2−/− embryos show overgrowth in restricted tissues of mesodermal lineage, displaying centrosome amplification and genomic instability. LATS2 localizes to centrosomes and overexpression of LATS2 suppresses centrosome over-duplication. These findings indicated an essential role of LATS2 in governing centrosome duplication, maintenance of mitotic fidelity and genomic stability.
LATS2 has also been proved to be involved in embryo development and epithelial-to-mesenchymal transitions (EMTs), and Snail1 is a central regulator of epithelial cell adhesion and movement in EMT. By screening human kinome RNAi, researchers have identified Lats2 kinase is a novel regulator that modulates Snail1 protein level, subcellular localization, and thus, activity. Lats2 interacts with Snail1 and directly phosphorylates Snail1 at residue T203. This occurs in the nucleus and retains Snail1 in the nucleus thereby enhancing its stability. Taken together, Lats2 positively influence cellular EMT and tumor cell invasion in a Snail1-dependent manner.
LATS2 is also closely related to ovarian cancer (OC). Previous studies have shown that the expression of miR-25 is increased in OC tissues and cell lines, and inhibition of miR-25 remarkably suppresses proliferation, migration and invasion of OC cells. LATS2 is confirmed to be a direct target of miR-25 in OC cells. Moreover, restoration of LATS2 significantly attenuated the oncogenic effects of miR-25. Taken together, these data suggest an oncogenic role of miR-25 in OC and a potentially novel diagnostic and therapeutic target for OC treatment.
References: